Evidence map›Paper›PMID 39354985›Full record

ArticleFrontiers in nuclear medicine2022

Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans.

Zsolt Cselényi, Aurelija Jucaite, Pär Ewing, Per Stenkrona, Cecilia Kristensson, Peter Johnström, Magnus Schou, Martin Bolin, Christer Halldin, Bengt Larsson and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03097380 (An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03097380 phase1completednot on this map

An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.

TypeinterventionalSponsorAstraZenecaRan2017 to 2017Enrolled19ConditionsHealthy VolunteersArmsAZD2115, SPIRIVA, [11C]AZ13754366
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zsolt CselényiPET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca AB, Stockholm, Sweden.
Aurelija JucaitePET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca AB, Stockholm, Sweden.
Pär EwingDMPK, Research & Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden.
Per StenkronaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Cecilia KristenssonClinical Development, Research & Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden.
Peter JohnströmPET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca AB, Stockholm, Sweden.
Magnus SchouPET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca AB, Stockholm, Sweden.
Martin BolinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Bengt LarssonDMPK, Research & Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden.
Ken GrimeClinical Development, Research & Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden.
Ulf G ErikssonClinical Development, Research & Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden.
Lars FardeDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Molecular imaging has not been used to support the development of drugs for the treatment of pulmonary disorders. The aim of the present translational study was to advance quantitative pulmonary PET imaging by demonstrating occupancy of the reference asthma drug tiotropium at muscarinic acetylcholine receptors (mAChR). Methods: PET imaging was performed using the muscarinic radioligand [ Results: There was an evident effect of tiotropium on [ Discussion: The results demonstrate that [ Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03097380.

Indexed as

[11C]VC-002lungmuscarinic receptorspositron emission tomographyreceptor occupancytiotropium

Identifiers

PMID39354985
PMCPMC11440881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.